Medartis Holding AG

MED

Equity

ISIN CH0386200239 / Valor 38620023

SIX Swiss Exchange (2025-10-17)

CHF 80.10-0.37%

Medartis Holding AG
UMushroom community rating:

5.00 1 votes No rating yet

NegativeNeutralPositive

About company

Medartis Holding AG is a global leader in the development and manufacturing of implants for osteosynthesis, focusing on cranio-maxillofacial surgery and upper and lower extremities. Their innovative products play a crucial role in the effective treatment of bone fractures, leading to shorter rehabilitation periods and enhanced quality of life for patients.

Summarized from source with an LLMView SourceSector: Healthcare

Robust Organic Sales Growth

Core sales surged by 15.3% organically in the first half of 2025, reaching CHF 122.1 million. This growth was primarily driven by mid-teens increases in both the EMEA and US regions, highlighting the company's effective market strategies and strong demand for its products.

Sustained EBITDA Margin

Medartis maintained a healthy core EBITDA margin of 17.8% despite facing challenges from CHF appreciation and US tariffs. This stability underscores the company’s operational efficiency and effective cost management.

Strategic Acquisitions and Market Expansion

The company secured the remaining 53% stake in KeriMedical in July, positioning itself for the US market introduction of its flagship product, TOUCH. Additionally, the integration of NeoOrtho in Brazil is progressing as planned, with back-office consolidation and a new production facility in Curitiba expected to be completed by early 2026.

Positive Regional Performance

EMEA and US regions both grew by 16%, with the EMEA region benefiting from strong sales in the UK and Spain. The US market saw double-digit growth, and strategic restructuring of distribution partners is set to enhance market presence further in the latter half of the year.

Summarized from source with an LLMView Source

Key figures

41.3%1Y

11.1%3Y

69.7%5Y

Performance

42.2%1Y

43.7%3Y

42.9%5Y

Volatility